Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Immuron Limited ( (AU:IMC) ) has provided an update.
Immuron Limited has announced the application for quotation of 314,843 ordinary fully paid securities on the Australian Securities Exchange (ASX), with an issue date of December 16, 2025. This move is part of the company’s strategic efforts to enhance its market presence and potentially increase its capital base, which could have implications for its operational capabilities and stakeholder interests.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
More about Immuron Limited
Immuron Limited is a company operating in the biotechnology industry, focusing on the development and commercialization of oral immunotherapy products. The company’s primary products are aimed at providing solutions for gut health and immune-related conditions.
Average Trading Volume: 1,056,012
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$12.68M
Find detailed analytics on IMC stock on TipRanks’ Stock Analysis page.